此报告仅供内部客户参考请务必阅读正文之后的免责条款部分证券研究报告622023二季度板块业绩加速修复，盈利能力环比改善2023年09月04日评级领先大市评级变动：维持行业涨跌幅比较%1M3M12M医疗器械-6.57-12.88-13.94沪深300-3.90-0.33-4.34邹建军分析师执业证书编号:S0530521080001zoujianjun@hnchasing.com龙靖宁研究助理longjingning@hnchasing.com重点股票2022A2023E2024E评级EPS（元）PE（倍）EPS（元）PE（倍）EPS（元）PE（倍）迈瑞医疗6.5840.938.0533.459.7627.59买入爱博医疗2.2174.753.1552.444.3637.89买入惠泰医疗5.3766.007.3748.099.9235.73增持正海生物1.5919.241.9915.372.2213.78增持我武生物0.6747.430.8238.761.0330.85增持诺唯赞1.4918.010.7336.771.2222.00增持澳华内镜0.16354.380.6587.231....